RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells

General Physiology and Biophysics

Volumn 28, Issue , 2009, Pages

  Leclerc, Estelle ^a   Heizmann, Claus W ^b   Vetter, Stefan W ^c  

^a NDSU   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Melanoma; RAGE; S100 protein; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM BINDING PROTEIN; CALCYCLIN; PROTEIN S 100; PROTEIN S100A10; PROTEIN S100A2; PROTEIN S100B; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MELANOMA CELL; METASTASIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A2; ANTIGENS, NEOPLASM; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHEMOTACTIC FACTORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; S100 PROTEINS; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 77149156908     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. Abe R., Shimizu T., Sugawara H., Watanabe H., Nakamura H., Choei H., Sasaki N., Yamagishi S., Takeuchi M., Shimizu H. (2004): Regulation of human melanoma growth and metastasis by AGE-AGEreceptor interactions. J. Invest. Dermatol. 122, 461-467
2. Abraha H. D., Fuller L. C., Du Vivier A. W., Higgins E. M., Sherwood R. A. (1997): Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br. J. Dermatol. 137, 381-385
3. Aisner D. L., Maker A., Rosenberg S. A., Berman D. M. (2005): Loss of S100 antigenicity in metastatic melanoma. Hum. Pathol. 36, 1016-1019
4. Ambartsumian N., Grigorian M., Lukanidin E. (2005): Genetically modified mouse models to study the role of metastasis-promoting S100A4(mts1) protein in metastatic mammary cancer. J. Dairy Res. 72, 27-33
5. Ambartsumian N., Klingelhofer J., Grigorian M., Christensen C., Kriajevska M., Tulchinsky E., Georgiev G., Berezin V., Bock E., Rygaard J., Cao R., Cao Y., Lukanidin E. (2001): The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 20, 4685-4695
6. Andres R., Mayordomo J. I., Visus C., Isla D., Godino J., Escudero P., Saenz A., Ortega E., Lastra R., Lambea J., Aguirre E., Elosegui L., Marcos I., Ruiz-Echarri M., Millastre E., Saez-Gutierrez B., Asin L., Vidal M. J., Ferrer A., Giner A., Larrad L., Carapeto F. J., Tres A. (2008): Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. Am. J. Clin. Oncol 31, 335-339
7. Baudier J., Delphin C., Grunwald D., Khochbin S., Lawrence J. J. (1992): Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc. Natl. Acad. Sci. U.S.A. 89, 11627-11631
8. Bianchi M. E. (2007): DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1-5
9. Bolander A., Agnarsdottir M., Wagenius G., Stromberg S., Ponten F., Ekman S., Brattstrom D., Larsson A., Einarsson R., Ullenhag G., Hesselius P., Bergqvist M. (2008): Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma. Melanoma Res. 18, 412-419
10. 2+-binding proteins S100A6 and S100B in primary cutaneous melanoma. J. Cutan. Pathol. 24, 76-80
11. Calabretta B., Kaczmarek L., Mars W., Ochoa D., Gibson C. W., Hirschhorn R. R., Baserga R. (1985): Cell-cycle-specific genes differentially expressed in human leukemias. Proc. Natl. Acad. Sci. U.S.A. 82, 4463-4467
12. Domoto T., Miyama Y., Suzuki H., Teratani T., Arai K., Sugiyama T., Takayama T., Mugiya S., Ozono S., Nozawa R. (2007): Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci. 98, 77-82
13. Donato R. (2009): S100B's double life: intracellular and extracellular signal. Biochim. Biophys. Acta 1793, 1008-1022
14. Donato R. (2007): RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr. Mol. Med. 7, 711-724
15. Donato R. (2003): Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 60, 540-551
16. 2+-binding protein family. Genes Dev. 3, 1086-1093
17. Egberts F., Pollex A., Egberts J. H., Kaehler K. C., Weichenthal M., Hauschild A. (2008): Long-term survival analysis in meta-static melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie 31, 380-384
18. El-Rifai W., Moskaluk C. A., Abdrabbo M. K., Harper J., Yoshida C., Riggins G. J., Frierson H. F. Jr., Powell S. M. (2002): Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 62, 6823-6826
19. Emberley E. D., Murphy L. C., Watson P. H. (2004): S100 proteins and their influence on pro-survival pathways in cancer. Biochem. Cell. Biol. 82, 508-515
20. Fernandez-Fernandez M. R., Rutherford T. J., Fersht A. R. (2008): Members of the S100 family bind p53 in two distinct ways. Protein Sci. 17, 1663-1670
21. Fernandez-Fernandez M. R., Veprintsev D. B., Fersht A. R. (2005): Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 102, 4735-4740
22. Foell D., Wittkowski H., Vogl T., Roth J. (2007): S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81, 28-37
23. Foser S., Redwanz I., Ebeling M., Heizmann C. W., Certa U. (2006): Interferon-alpha and transforming growth factor-beta co-induce growth inhibition of human tumor cells. Cell. Mol. Life Sci. 63, 2387-2396
24. Fuentes M. K., Nigavekar S. S., Arumugam T., Logsdon C. D., Schmidt A. M., Park J. C., Huang E. H. (2007): RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis. Colon Rectum 50, 1230-1240
25. Gerke V., Weber K. (1984): Identity of p36K phosphorylated upon Rous sarcoma virus transformation with a protein purified from brush borders; calcium-dependent binding to non-erythroidspectrin and F-actin. Embo J. 3, 227-233
26. Glenney J. R. Jr., Tack B. F. (1985): Amino-terminal sequence of p36 and associated p10, identification of the site of tyrosine phosphorylation and homology with S-100. Proc. Natl. Acad. Sci. U.S.A. 82,7884-7888
27. Gollob J. A., Sciambi C. J. (2007): Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin. Cancer Res. 13, 5219-5225
28. Hamberg A. P., Korse C. M., Bonfrer J. M., deGast G. C. (2003): Serum S100B is suitable for prediction and monitoring of response to chemo-immunotherapy in metastatic malignant melanoma. Melanoma Res. 13, 45-49
29. Hansson L. O., von Schoultz E., Djureen E., Hansson J., Nilsson B., Ringborg U. (1997): Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res. 17, 3071-3073
30. Harpio R., Einarsson R. (2004): S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin. Biochem. 37, 512-518
31. Hauschild A., Engel G., Brenner W., Glaser R., Monig H., Henze E., Christophers E. (1999): S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56, 338-344
32. Heizmann C. W. (2002): The multifunctional S100 protein family. Methods Mol. Biol. 172, 69-80
33. Heizmann C. W. (2004): S100B protein in clinical diagnostics: assay specificity. Clin. Chem. 50, 249-251
34. Heizmann C. W., Ackermann G. E., Galichet A. (2007): Pathologies involving the S100 proteins and RAGE. Subcell. Biochem. 45, 93-138
35. Heizmann C. W., Fritz G., Schäfer B. W. (2002): S100 proteins: structure, functions and pathology. Front. Biosci. 7, d1356-1368
36. Hough C. D., Cho K. R., Zonderman A. B., Schwartz D. R., Morin P. J. (2001): Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61, 3869-3876
37. Hudson B. I., Harja E., Moser B., Schmidt A. M. (2005): Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler. Thromb. Vase. Biol. 25, 879-882
38. Hudson B. I., Carter A. M., Harja E., Kalea A. Z., Arriero M., Yang H., Grant P. J., Schmidt A. M. (2008): Identification, classification, and expression of RAGE gene splice variants. Faseb J. 22, 1572-1580
39. Karnell R., von Schoultz E., Hansson L. O., Nilsson B., Arstrand K., Kagedal B. (1997): S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5- methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 7, 393-399
40. Kashani-Sabet M., Rangel J., Torabian S., Nosrati M., Simko J., Jablons D. M., Moore D. H., Haqq C., Miller J. R. 3rd, Sagebiel R. W. (2009): A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc. Natl. Acad. Sci. U.S.A. 106, 6268-6272
41. 2+-binding protein. FEBS Lett. 254, 141-144
42. Kuznicki J., Filipek A., Hunziker P. E., Huber S., Heizmann C. W. (1989): Calcium-binding protein from mouse Ehrlich ascites-tumour cells is homologous to human calcyclin. Biochem. J. 263, 951-956
43. Leclerc E., Fritz G., Vetter S. W., Heizmann C. W. (2009): Binding of S100 proteins to RAGE: An update. Biochim. Biophys. Acta 1793, 993-1007
44. Lee S. W., Tomasetto C., Swisshelm K., Keyomarsi K., Sager R. (1992): Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxyeytidine treatment. Proc. Natl. Acad. Sci. U.S.A. 89, 2504-2508
45. Logsdon C. D., Fuentes M. K., Huang E. H., Arumugam T. (2007): RAGE and RAGE ligands in cancer. Curr. Mol. Med. 7, 777-789
46. Maelandsmo G. M., Florenes V. A., Mellingsaeter T., Hovig E., Kerbel R. S., Fodstad O. (1997): Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int. J. Cancer 74, 464-469
47. Markowitz J., Mackerell A. D. Jr., Carrier E., Charpentier T. H., Weber D. J. (2005): Design of inhibitors for S100B. Curr. Top. Med. Chem. 5, 1093-1108
48. Marenholz I., Lovering R. C., Heizmann C. W. (2006): An update of the S100 nomenclature. Biochim. Biophys. Acta 1763, 1282-1283
49. Mass R. D. (2004): The HER receptor family: a rich target for therapeutic development. Int. J. Radiat. Oncol. Biol. Phys. 58, 932-940
50. Mueller A., Schäfer B. W., Ferrari S., Weibel M., Makek M., Hochli M., Heizmann C. W. (2005): The calciumbinding protein S100A2 interacts with p53 and modulates its transcriptional activity. J. Biol. Chem. 280, 29186-29193
51. Nagy N., Brenner C., Markadieu N., Chaboteaux C., Camby I., Schafer B. W., Pochet R., Heizmann C. W., Salmon I., Kiss R., Decaestecker C. (2001): S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab. Invest. 81, 599-612
52. Natan E., Hirschberg D., Morgner N., Robinson C. V., Fersht A. R. (2009): Ultraslow oligomerization equilibria of p53 and its implications. Proc. Natl. Acad. Sci. U.S.A. 106, 14327-14332
53. Nonaka D., Chiriboga L., Rubin B. P. (2008): Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J. Cutan. Pathol. 35, 1014-1019
54. Oberholzer P. A., Urosevic M., Steinert H. C., Dummer R. (2008): Baseline staging of melanoma with unknown primary site: the value of serum S100 protein and positron emission tomography. Dermatology 217, 351-355
55. Petersson S., Shubbar E., Enerback L., Enerback C. (2009): Expression patterns of S100 proteins in melanocytes and melanocytic lesions. Melanoma Res. 19, 215-225
56. Ramasamy R., Yan S. F., Schmidt A. M. (2009): RAGE: therapeutic target and biomarker of the inflammatory response - the evidence mounts. J. Leukoc. Biol. 86, 505-512
57. Rescher U., Gerke V. (2008): S100A10/p11: family, friends and functions. Pflugers Arch. 455, 575-582
58. Rety S., Sopkova J., Renouard M., Osterloh D., Gerke V., Tabaries S., Russo-Marie F., Lewit-Bentley A. (1999): The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nat. Struct. Biol. 6, 89-95
59. Ribé A., McNutt N. S. (2003): S100A6 protein expression is different in Spitz nevi and melanomas. Mod. Pathol. 16, 505-511
60. Rust R., Visser L., van derLeij J., Harms G, Blokzijl T., Deloulme J. C., van derVlies P., Kamps W., Kok K., Lim M., Poppema S., van den Berg A. (2005): High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma. Br. J. Haematol. 131, 596-608
61. 2+-dependent interaction of S100B(beta beta) with a peptide derived from p53. Biochemistry 37, 1951-1960
62. Rustandi R. R., Baldisseri D. M., Weber D. J. (2000): Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat. Struct. Biol. 7, 570-574
63. Schmidt A. M., Yan S. D., Yan S. F., Stern D. M. (2000): The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498, 99-111
64. 2+-binding S100 proteins in epithelial tumours of the skin. Virchows Arch. 432, 53-59
65. Schultz E. S., Diepgen T. L., Von Den Driesch P. (1998): Clinical and prognostic relevance of serum S-100b protein in maligant melanoma. Br. J. Dermatol. 138, 426-430
66. Spandidos A., Wang X., Wang H., Dragnev S., Thurber T., Seed B. (2008): A comprehensive collection of experimentally validated primers for Polymerase Chain Reaction quantitation of murine transcript abundance. BMC Genomics 9, 633-650
67. Sparvero L. J., Asafu-Adjei D., Kang R., Tang D., Amin N., Im J., Rutledge R., Lin B., Amoscato A. A., Zeh H. J., Lotze M. T. (2009): RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 7, 17-38
68. 2+-dependent association of S100A6 (calcyclin) with the plasma membrane and the nuclear envelope. J. Biol. Chem. 274, 31593-31596
69. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., Nguyen M., Olsson A., Nawroth P. P., Bierhaus A., Varki N., Kronenberg M., Freeze H. H., Srikrishna G. (2008): RAGE, carboxylatedglycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29, 2035-2043
70. Van Ginkel P. R., Gee R. L., Walker T. M., Hu D. N., Heizmann C. W., Polans A. S. (1998): The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim. Biophys. Acta 1448, 290-297
71. Vimalachandran D., Greenhalf W., Thompson C., Luttges J., Prime W., Campbell F., Dodson A., Watson R., Crnogorac-Jurcevic T., Lemoine N., Neoptolemos J., Costello E. (2005): High nuclear S100A6 (calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res. 65, 3218-3225
72. Viros A., Fridlyand J., Bauer J., Lasithiotakis K., Garbe C., Pinkel D., Bastian B. C. (2008): Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5, e120
73. Von Schoultz E., Hansson L. O., Djureen E., Hansson J., Karnell R., Nilsson B., Stigbrand T, Ringborg U. (1996): Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res. 6,133-137
74. Wang X., Seed B. (2003): A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 31, e154
75. Weterman M. A., Stoopen G M., van Muijen G. N., Kuznicki J., Ruiter D. J., Bloemers H. P. (1992): Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice. Cancer Res. 52, 1291-1296
76. Weterman M. A., van Muijen G. N., Bloemers H. P., Ruiter D. J. (1993): Expression of calcyclin in human melanocytic lesions. Cancer Res. 53, 6061-6066
77. Zhang L, Fogg D. K., Waisman D. M. (2004): RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells. J. Biol. Chem. 279, 2053-2062
78. Zimmer D. B., Cornwall E. H., Landar A., Song W (1995): The S100 protein family: history, function, and expression. Brain Res. Bull. 37, 417-429
79. Zimmer D. B., Wright Sadosky P., Weber D. J. (2003): Molecular mechanisms of S100-target protein interactions. Microsc. Res. Tech. 60, 552-559